Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Hematological malignancy amid COVID-19

Naval Daver • 18 Apr 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia General Leukemia Venetoclax

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses how the COVID-19 pandemic is impacting the treatment of patients with hematological malignancy and what is being done to combat issues that have arisen. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Naval Daver

New treatments in AML: FLT3 inhibitors & novel combinations
Gail Roboz et al. • 4 Sep 2023
3:53
Investigating the combination of pivekimab sunirine, azacitidine & venetoclax in R/R AML
Naval Daver • 12 Dec 2022
1:13
The importance of CD47 as a target in MDS and AML
Naval Daver • 12 Dec 2022
3:50
Investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with AML
Naval Daver • 12 Dec 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals